PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity
Authors
Keywords
-
Journal
CELL BIOCHEMISTRY AND FUNCTION
Volume 32, Issue 4, Pages 368-377
Publisher
Wiley
Online
2014-02-25
DOI
10.1002/cbf.3025
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing
- (2013) J. Jeyabalan et al. OSTEOPOROSIS INTERNATIONAL
- Hypothermia inhibits osteoblast differentiation and bone formation but stimulates osteoclastogenesis
- (2012) Jessal J. Patel et al. EXPERIMENTAL CELL RESEARCH
- Recent UK trends in the unequal burden of coronary heart disease
- (2012) Jonathan Pearson-Stuttard et al. HEART
- Forecasting the Future of Cardiovascular Disease in the United States
- (2011) Paul A. Heidenreich et al. CIRCULATION
- Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats
- (2011) Claudia Sedlinsky et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Rosiglitazone Decreases Bone Mass and Bone Marrow Fat
- (2011) Torben Harsløf et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
- (2011) Goodarz Danaei et al. LANCET
- Forming functional fat: a growing understanding of adipocyte differentiation
- (2011) Ana G. Cristancho et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
- (2011) Astrid K Stunes et al. BMC Endocrine Disorders
- Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors
- (2010) Fanny Lalloyer et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass
- (2010) M. Shah et al. BONE
- AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts
- (2010) Young-Sun Lee et al. BONE
- Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
- (2010) R. E. Aubert et al. DIABETES OBESITY & METABOLISM
- The Effect of Metformin on Alveolar Bone in Ligature-Induced Periodontitis in Rats: A Pilot Study
- (2010) Eun Jung Bak et al. JOURNAL OF PERIODONTOLOGY
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
- (2010) Min Jun et al. LANCET
- High serum total cholesterol is a long-term cause of osteoporotic fracture
- (2010) P. Trimpou et al. OSTEOPOROSIS INTERNATIONAL
- THIAZOLIDINEDIONES INHIBIT TNF-α-MEDIATED OSTEOCLAST DIFFERENTIATION OF RAW264.7 MACROPHAGES AND MOUSE BONE MARROW CELLS THROUGH DOWNREGULATION OF NFATc1
- (2010) Chia-Ron Yang et al. SHOCK
- PPARs in Bone: The Role in Bone Cell Differentiation and Regulation of Energy Metabolism
- (2010) Beata Lecka-Czernik Current Osteoporosis Reports
- Global estimates of the prevalence of diabetes for 2010 and 2030
- (2009) J.E. Shaw et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effect of metformin on bone marrow progenitor cell differentiation: In vivo and in vitro studies
- (2009) M Silvina Molinuevo et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Hypoxia stimulates vesicular ATP release from rat osteoblasts
- (2009) Isabel R. Orriss et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes
- (2009) Daniel H. Solomon et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes
- (2009) Bernard Zinman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
- (2009) Unni Syversen et al. BMC Endocrine Disorders
- Transcription factors controlling osteoblastogenesis
- (2008) Pierre J. Marie ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Use of Thiazolidinediones and Fracture Risk
- (2008) Christian Meier et al. ARCHIVES OF INTERNAL MEDICINE
- A novel PPARγ agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways
- (2008) Ju-Young Park et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Diabetes and fragility fractures — A burgeoning epidemic?
- (2008) Sol Epstein et al. BONE
- The Peroxisome Proliferator Activator Receptor Alpha/Delta Agonists Linoleic Acid and Bezafibrate Upregulate Osteoblast Differentiation and Induce Periosteal Bone Formation In Vivo
- (2008) Karen Still et al. CALCIFIED TISSUE INTERNATIONAL
- Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)
- (2008) S. E. Kahn et al. DIABETES CARE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search